Atyr PHARMA (NASDAQ:ATYR - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Atyr PHARMA to post earnings of ($0.19) per share for the quarter.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. On average, analysts expect Atyr PHARMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Atyr PHARMA Price Performance
Shares of NASDAQ:ATYR traded down $0.10 on Friday, hitting $3.35. The company's stock had a trading volume of 631,212 shares, compared to its average volume of 899,533. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company has a 50-day simple moving average of $3.36 and a 200 day simple moving average of $3.35. The company has a market capitalization of $297.68 million, a PE ratio of -3.56 and a beta of 0.95. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66.
Wall Street Analyst Weigh In
ATYR has been the topic of a number of research analyst reports. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Friday, March 14th. Leerink Partners initiated coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price objective on the stock. Finally, Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an "overweight" rating for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $18.60.
Check Out Our Latest Analysis on ATYR
Atyr PHARMA Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
